Platelet pharmacogenomics.
J Thromb Haemost. 2010 Jun;8(6):1147-58
Authors: Zuern CS, Schwab M, Gawaz M, Geisler T
Platelet responsiveness to conventional antiplatelet therapy underlies a high interindividual variability influenced by various factors.
Clinical Drugs Undergoing Polymorphic Metabolism by Human Cytochrome P450 2C9 and the Implication in Drug Development.
Curr Med Chem. 2010 Dec 24;
Authors: He SM, Zhou ZW, Li XT, Zhou SF
CYP2C9 metabolizes more than 100 clinically used drugs including phenytoin, S-warfarin, tolbutamide, glipizide, diclofenac, and losartan with varying contributions. CYP2C9 is considered one of the most important CYPs, with substrate specificity typical of many new chemical entities (i. e.
[Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?].
Cas Lek Cesk. 2010;149(10):476-81
Authors: Bultas J
In clinical practice the individual response to a drug represents a great problem. Many of us experienced a situation when the drug effect declined or drug-related toxic reaction occurred. The typical example is the variation of optimal warfarin dosage.
[Pharmacogenetic aspects of current pharmacotherapy].
Cas Lek Cesk. 2010;149(10):472-5
Authors: Slanar O, Zima T
Pharmacogenetics is a specific area of personalized medicine. Pharmacogenetic testing is in the ideal situation conducted prior to the initiation of pharmacotherapy in order to increase efficacy or to minimize risk of toxicity in predisposed patients.
The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
Br J Clin Pharmacol. 2010 Dec;70(6):844-853
Authors: Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, Tingle MD
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The prodrug cyclophosphamide requires bioactivation by liver CYP enzymes. • Controversy exists about which CYP isoforms are important in the in vitro bioactivation of this drug.
VKORC1 Pharmacogenetics and Pharmacoproteomics in Patients on Warfarin Anticoagulant Therapy: Transthyretin Precursor as a Potential Biomarker.
PLoS One. 2010;5(12):e15064
Authors: Saminathan R, Bai J, Sadrolodabaee L, Karthik GM, Singh O, Subramaniyan K, Ching CB, Chen WN, Chowbay B
BACKGROUND: Recognizing specific protein changes in response to drug administration in humans has the potential for the development of personalized medicine.
Methotrexate pharmacogenetics in rheumatoid arthritis.
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S33-9
Authors: Brinker RR, Ranganathan P
Rheumatoid arthritis (RA) is a systemic inflammatory arthritis that can not only result in permanent joint damage, but is associated with high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the mainstay of treatment in RA.
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
J Clin Pharm Ther. 2010 Jun;35(3):343-50
Authors: Lee VW, Chau TS, Chan AK, Lee KK, Waye MM, Ling TK, Chan FK
Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients.
Targeting c-Myc as a novel approach for hepatocellular carcinoma.
World J Hepatol. 2010 Jan 27;2(1):16-20
Authors: Lin CP, Liu CR, Lee CN, Chan TS, Liu HE
Hepatocelluar carcinoma (HCC) is the most lethal cancer in the world. Most HCC over-express c-Myc, which plays a critical role in regulating cellular growth, differentiation and apoptosis in both normal and neoplastic cells.
Pharmacogenetics: so near and yet so far?
J Hypertens. 2010 Apr;28(4):671-2
Authors: Freel EM
PMID: 20625249 [PubMed - indexed for MEDLINE]